Comparison
Omega-3 (EPA/DHA) vs Thymosin Alpha-1
Side-by-side of Omega-3 (EPA/DHA) and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Thymosin Alpha-1
Thymosin alpha-1 peptide (Zadaxin, thymalfasin): 28-amino-acid TA1 immunomodulator. Dosing, T-cell effects, hepatitis B and HCV adjunct evidence.
Effects at a glance
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Thymosin Alpha-1
- •28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
- •Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
- •Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
- •Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
- •Standard label dose: 1.6 mg subcutaneously twice weekly
- •Cleanest safety profile in the peptide class with hundreds of regulated trials behind it
Side-by-side
| Attribute | Omega-3 (EPA/DHA) | Thymosin Alpha-1 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | fish oil, EPA, DHA, marine omega-3 | Talpha1, Ta1, Zadaxin, Thymalfasin |
| Half-life (hr) ↗ | 48 | 2 |
| Typical dose (mg) ↗ | 2000 | 1.6 |
| Dosing frequency | 1 to 2 times daily with food | 2x weekly |
| Routes | oral | subcutaneous, intramuscular |
| Onset (hr) | 4 | 24 |
| Peak (hr) | 12 | 168 |
| Molecular weight | 302.45 | 3108.32 |
| Molecular formula | C20H30O2 (EPA); C22H32O2 (DHA) | C129H215N33O55 |
| Mechanism | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. | Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells. |
| Legal status | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia | Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled | Rx only via international approval or US compounding (no controlled-substance schedule) |
| Pregnancy | Recommended at 200 to 600 mg DHA/day for fetal development | Not recommended; insufficient data |
| CAS | 10417-94-4 | 62304-98-7 |
| PubChem CID | 446284 | 16130571 |
| Wikidata | Q207688 | Q913854 |
Safety profile
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Thymosin Alpha-1
Common side effects
- mild injection-site irritation (rare)
- transient mild fatigue (rare)
- occasional headache (rare)
Contraindications
- pregnancy
- lactation
- active organ transplant rejection therapy
- systemic immunosuppression for autoimmune disease (relative)
- severe active autoimmune disease (caution)
Interactions
- interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
- calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
- antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
- vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is healthspan extension, pick Omega-3 (EPA/DHA).
- → If your priority is immune support, pick Thymosin Alpha-1.
- → If your priority is post-training recovery, pick Thymosin Alpha-1.
Edge case: If you want to avoid Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Omega-3 (EPA/DHA) and Thymosin Alpha-1?
Omega-3 (EPA/DHA) and Thymosin Alpha-1 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Omega-3 (EPA/DHA) or Thymosin Alpha-1?
Omega-3 (EPA/DHA) half-life is 48 hours; Thymosin Alpha-1 half-life is 2 hours.
Can you stack Omega-3 (EPA/DHA) with Thymosin Alpha-1?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper